Literature DB >> 25060376

2014 hypertension recommendations from the eighth joint national committee panel members raise concerns for elderly black and female populations.

Lawrence R Krakoff1, Robert L Gillespie2, Keith C Ferdinand3, Icilma V Fergus4, Ola Akinboboye5, Kim A Williams6, Mary Norine Walsh7, C Noel Bairey Merz8, Carl J Pepine9.   

Abstract

A report from panel members appointed to the Eighth Joint National Committee titled "2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults" has garnered much attention due to its major change in recommendations for hypertension treatment for patients ≥60 years of age and for their treatment goal. In response, certain groups have opposed the decision to initiate pharmacologic treatment to lower blood pressure (BP) at systolic BP ≥150 mm Hg and treat to a goal systolic BP of <150 mm Hg in the general population age ≥60 years. This paper contains 3 sections-an introduction followed by the opinions of 2 writing groups-outlining objections to or support of maintaining this proposed strategy in certain at-risk populations, namely African Americans, women, and the elderly. Several authors argue for maintaining current targets, as opposed to adopting the new recommendations, to allow for optimal treatment for older women and African Americans, helping to close sex and race/ethnicity gaps in cardiovascular disease morbidity and mortality.
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  hypertension and prevention/hypertension; quality of care and outcomes assessment/appropriateness; quality of care and outcomes assessment/quality of care

Mesh:

Substances:

Year:  2014        PMID: 25060376      PMCID: PMC4242519          DOI: 10.1016/j.jacc.2014.06.014

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  55 in total

1.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors:  E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

2.  Proportion of US adults potentially affected by the 2014 hypertension guideline.

Authors:  Ann Marie Navar-Boggan; Michael J Pencina; Ken Williams; Allan D Sniderman; Eric D Peterson
Journal:  JAMA       Date:  2014-04-09       Impact factor: 56.272

3.  Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease.

Authors:  V Schächinger; M B Britten; A M Zeiher
Journal:  Circulation       Date:  2000-04-25       Impact factor: 29.690

Review 4.  Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  Cheryl Bushnell; Louise D McCullough; Issam A Awad; Monique V Chireau; Wende N Fedder; Karen L Furie; Virginia J Howard; Judith H Lichtman; Lynda D Lisabeth; Ileana L Piña; Mathew J Reeves; Kathryn M Rexrode; Gustavo Saposnik; Vineeta Singh; Amytis Towfighi; Viola Vaccarino; Matthew R Walters
Journal:  Stroke       Date:  2014-02-06       Impact factor: 7.914

5.  Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view.

Authors:  Jackson T Wright; Lawrence J Fine; Daniel T Lackland; Gbenga Ogedegbe; Cheryl R Dennison Himmelfarb
Journal:  Ann Intern Med       Date:  2014-04-01       Impact factor: 25.391

6.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).

Authors:  Paul A James; Suzanne Oparil; Barry L Carter; William C Cushman; Cheryl Dennison-Himmelfarb; Joel Handler; Daniel T Lackland; Michael L LeFevre; Thomas D MacKenzie; Olugbenga Ogedegbe; Sidney C Smith; Laura P Svetkey; Sandra J Taler; Raymond R Townsend; Jackson T Wright; Andrew S Narva; Eduardo Ortiz
Journal:  JAMA       Date:  2014-02-05       Impact factor: 56.272

7.  Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study.

Authors:  R S Vasan; M G Larson; E P Leip; W B Kannel; D Levy
Journal:  Lancet       Date:  2001-11-17       Impact factor: 79.321

8.  Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration.

Authors:  B Neal; S MacMahon; N Chapman
Journal:  Lancet       Date:  2000-12-09       Impact factor: 79.321

9.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

10.  Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension.

Authors:  Michael A Weber; Ernesto L Schiffrin; William B White; Samuel Mann; Lars H Lindholm; John G Kenerson; John M Flack; Barry L Carter; Barry J Materson; C Venkata S Ram; Debbie L Cohen; Jean-Claude Cadet; Roger R Jean-Charles; Sandra Taler; David Kountz; Raymond Townsend; John Chalmers; Agustin J Ramirez; George L Bakris; Jiguang Wang; Aletta E Schutte; John D Bisognano; Rhian M Touyz; Dominic Sica; Stephen B Harrap
Journal:  J Hypertens       Date:  2014-01       Impact factor: 4.844

View more
  36 in total

Review 1.  Recognition and Management of Hypertension in Older Persons: Focus on African Americans.

Authors:  Carolyn H Still; Keith C Ferdinand; Gbenga Ogedegbe; Jackson T Wright
Journal:  J Am Geriatr Soc       Date:  2015-10       Impact factor: 5.562

2.  BP Targets in Older Adults with CKD: Additional Evidence, but Uncertainty Continues.

Authors:  Sankar D Navaneethan; Adam Whaley-Connell
Journal:  Clin J Am Soc Nephrol       Date:  2015-08-14       Impact factor: 8.237

3.  The Role of Hypertension in Race-Ethnic Disparities in Cardiovascular Disease.

Authors:  Pelbreton C Balfour; Carlos J Rodriguez; Keith C Ferdinand
Journal:  Curr Cardiovasc Risk Rep       Date:  2015-04

Review 4.  Hypertension in African Americans.

Authors:  Nomsa Musemwa; Crystal A Gadegbeku
Journal:  Curr Cardiol Rep       Date:  2017-10-28       Impact factor: 2.931

5.  Incidence of cardiovascular disease in individuals affected by recent changes to US blood pressure treatment guidelines.

Authors:  Matthew Nayor; Meredith S Duncan; Solomon K Musani; Vanessa Xanthakis; Michael P LaValley; Martin G Larson; Ervin R Fox; Ramachandran S Vasan
Journal:  J Hypertens       Date:  2018-02       Impact factor: 4.844

Review 6.  Current and Future Treatment of Hypertension in the SPRINT Era.

Authors:  Robert A Phillips
Journal:  Methodist Debakey Cardiovasc J       Date:  2015 Oct-Dec

Review 7.  Primary and secondary prevention of ischemic heart disease in women.

Authors:  Priya Kohli
Journal:  Curr Atheroscler Rep       Date:  2015-07       Impact factor: 5.113

Review 8.  A Comparison of Vasodilating and Non-vasodilating Beta-Blockers and Their Effects on Cardiometabolic Risk.

Authors:  Icilma V Fergus; Kenneth L Connell; Keith C Ferdinand
Journal:  Curr Cardiol Rep       Date:  2015-06       Impact factor: 2.931

9.  The High Blood Pressure-Malaria Protection Hypothesis.

Authors:  Julio Gallego-Delgado; Thomas Walther; Ana Rodriguez
Journal:  Circ Res       Date:  2016-09-22       Impact factor: 17.367

10.  Implications of the Eighth Joint National Committee Guidelines for the Management of High Blood Pressure for Aging Adults: Atherosclerosis Risk in Communities Study.

Authors:  Michael D Miedema; Faye L Lopez; Michael J Blaha; Salim S Virani; Josef Coresh; Christie M Ballantyne; Aaron R Folsom
Journal:  Hypertension       Date:  2015-07-06       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.